Low dose warfarin treatment for calcinosis in patients with systemic sclerosis.

Abstract

OBJECTIVE:

To evaluate the effect of low doses of warfarin in patients with systemic sclerosis with disseminated subcutaneous calcinosis.

METHODS:

Three patients with disseminated subcutaneous calcinosis were treated with low doses of warfarin for 1 year. Subcutaneous calcinotic lesions, coagulation blood parameters, and the tendency for bleeding were followed up during the year.

RESULTS:

Two of the patients, who had newly diagnosed, diffuse, and relatively small calcinotic lesions, responded to warfarin treatment, with complete resolution of the calcinosis. The other patient, with larger and longer standing calcinotic lesions, did not respond to warfarin treatment. None of the three patients showed a prolongation of prothrombin time or partial thromboplastin time, nor did any have an increased tendency for bleeding.

CONCLUSIONS:

Low dose warfarin may serve as an effective treatment for calcinosis in a selected group of patients who have small and relatively new onset calcinosis. This treatment does not prolong the coagulation of blood and there is no increased tendency for bleeding.

• Authors: T Cukierman, E Elinav, M Korem, T Chajek-Shaul
• Journal: Annals of the rheumatic diseases (Ann Rheum Dis) Vol. 63 Issue 10 Pg. 1341-3 (Oct 2004) ISSN: 0003-4967 [Print] England
• PMID: 15361398 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Dermatologic Agents
• Warfarin

Topics

• Adult
• Aged
• Calcinosis (drug therapy, etiology)
• Dermatologic Agents (administration & dosage)
• Drug Administration Schedule
• Female
• Humans
• Scleroderma, Systemic (complications)
• Skin Diseases (drug therapy, etiology)
• Warfarin (administration & dosage)